10-Q: Picard Medical Completes IPO, Raises $17M Amid Rising Losses

Picard Medical, Inc. completed its Initial Public Offering, raising $17 million in gross proceeds, despite reporting a significant increase in net loss and ongoing operational challenges for the first half of 2025.

Summary

• Picard Medical, Inc. (PMI) completed its Initial Public Offering (IPO) on September 2, 2025, issuing 4,250,000 shares at $4.00 per share, generating $17.0 million in gross proceeds and $11.2 million in net proceeds.
• An underwriter over-allotment closing on September 9, 2025, added another $2.6 million in gross proceeds ($2.35 million net) from 637,500 shares.
• The company reported a net loss of $12.285 million for the six months ended June 30, 2025, a 104% increase from $6.011 million in the same period of 2024.
• Total revenues increased by 3% to $2.744 million for the first half of 2025, primarily driven by a 5% increase in product sales, while rental revenues ceased.
• Cost of revenues surged by 44% to $3.229 million, leading to a gross loss of $0.485 million, compared to a gross profit of $0.425 million in the prior year period.
• Operating expenses saw a modest 3% increase to $6.282 million, with R&D decreasing by 5% and SG&A increasing by 5%.
• Interest expense dramatically increased by 1074% to $2.982 million, and derivative loss soared by 4007% to $2.505 million, significantly contributing to the overall loss.
• All outstanding 2023 and 2024 Convertible Notes, totaling $14.752 million, were automatically converted into 19,634,860 shares of common stock in connection with the IPO.
• A 1 for 2.2 forward stock split on July 3, 2025, followed by a 1.0221 for 1 reverse stock split on July 11, 2025, resulted in an overall 1 for 2.1524 forward stock split, and authorized common stock increased to 150,000,000 shares.
• Hunniwell converted all Series A-1 Preferred Stock (39,618,919 shares) to common stock on July 7, 2025.
• The company identified material weaknesses in internal control over financial reporting, including lack of segregation of duties, formal review processes, written policies, and controls over related party transactions, and has a remediation plan in place.

Sentiment

Score: 4

Explanation: While the successful IPO is a significant positive, the company's underlying operational performance shows a substantial increase in net loss, a shift from gross profit to gross loss, and persistent going concern doubts. High interest and derivative losses, coupled with ongoing internal control weaknesses and past-due debt, indicate significant financial challenges despite the capital infusion.

Positives

• Successfully completed an Initial Public Offering (IPO) on September 2, 2025, raising $17.0 million in gross proceeds and an additional $2.6 million from over-allotment, providing crucial capital.
• Net cash used in operating activities decreased to $4.782 million for the six months ended June 30, 2025, from $6.114 million in the prior year, indicating an improvement in operational cash burn.
• Total revenues increased by 3% for the six months ended June 30, 2025, primarily driven by a 5% increase in product sales, demonstrating continued market demand for its core product.
• Issued a new U.S. Patent (No. 12,383,722 B2) in August 2025, covering core technology for its next-generation total artificial heart system, strengthening its intellectual property portfolio.
• Research and development expenses decreased by 5% for the six months ended June 30, 2025, potentially indicating efficiency gains or a shift in R&D focus.

Negatives

• Net loss more than doubled, increasing by 104% to $12.285 million for the six months ended June 30, 2025, compared to $6.011 million in the same period last year.
• Gross profit turned into a gross loss of $0.485 million for the six months ended June 30, 2025, a 214% decrease from a gross profit of $0.425 million in the prior year, primarily due to a 44% increase in cost of revenues.
• Operating loss increased by 19% to $6.767 million for the six months ended June 30, 2025.
• Interest expense surged by 1074% to $2.982 million, and derivative loss increased by 4007% to $2.505 million, significantly impacting profitability.
• The company continues to have substantial doubt about its ability to continue as a going concern, despite the IPO, indicating ongoing financial fragility.
• Material weaknesses in internal control over financial reporting persist, including lack of segregation of duties, formal review processes, written policies, and controls over related party transactions.
• Several convertible notes, including $0.325 million of 2023 notes and $3.7 million of 2024 notes, as well as the $3.5 million Nexus note, are past due.
• Rental revenues completely ceased for the six months ended June 30, 2025, down from $57,000 in the prior year.

Risks

• Changes in applicable laws or regulations could adversely affect operations.
• Regulatory approvals may not be obtained, be delayed, or be subject to unanticipated conditions.
• Impact of pandemics or other national or international health-related events.
• Risk of financial or liquidity crises.
• Effects of inflation and changes in interest rates.
• Geopolitical factors, including the Russian invasion of Ukraine and the Israel-Hamas conflict.
• Risk of global and regional economic downturns.
• Uncertainty regarding projected financial information, anticipated growth rate, and market opportunity.
• Foreign currency, interest rate, and exchange rate fluctuations.
• Challenges in retention or recruitment of executive and senior management and other key employees.
• Ability to maintain an effective system of internal controls over financial reporting.
• Ability to manage growth effectively.
• Ability to achieve and maintain profitability in the future.
• Ability to access sources of capital to finance operations and growth.
• Success of strategic relationships with third parties.
• Dependence on acquisitions for business growth.
• Ability to develop new products and solutions, bring them to market in a timely manner, and make enhancements to the platform.
• Performance of the business.
• Development, effects, and enforcement of laws and regulations.
• Inherent risks related to acquisitions and the ability to manage growth and changing business.
• Need for significant financial resources (including for business growth).
• Need for financing to maintain future profitability.
• Lack of any assurance or guarantee that capital can be raised or funding needs met.
• Limited operating history.
• Potential for material losses from legal claims or litigation.

Future Outlook

The company expects operating losses and negative cash flows to continue into the foreseeable future, requiring additional debt and/or equity financing to fund operations until positive cash flows are generated. The IPO proceeds are expected to fund operations into 2025 based on the current business plan. The company aims to build a portfolio of medical technology companies in the cardiovascular space through acquisitions, development, or in-licensing, focusing on approved or near-approval devices. Product development is focused on improving clinical outcomes, usability, and patient quality of life for successive generations of the SynCardia TAH.

Management Comments

• Management believes that the amount, or range, of reasonably possible losses in connection with any pending legal actions against it in excess of established reserves, in the aggregate, is not material to its consolidated financial condition or cash flows.
• Management believes, based on a variety of factors, it is more likely than not that the deferred income tax assets will not be fully realized.
• Management is implementing measures to remediate material weaknesses in internal control over financial reporting, including hiring additional accounting personnel, establishing multi-level reviews, developing formal policies, and improving related party transaction monitoring.

Industry Context

Picard Medical operates in the specialized cardiovascular medical technology sector, focusing on total artificial hearts. Its SynCardia TAH is noted as the only FDA-approved and commercially available total artificial heart in the U.S. as a bridge to heart transplant. The company's strategy to build a portfolio through acquisitions, development, or in-licensing aligns with broader trends in the medical device industry where companies seek to expand their product offerings and market reach, often through strategic partnerships or M&A. The focus on next-generation devices and expanding patent protection indicates a commitment to innovation in a highly competitive and regulated field.

Comparison to Industry Standards

• The SynCardia TAH is highlighted as the only FDA-approved and commercially available total artificial heart in the United States as a bridge to heart transplant, positioning it uniquely against other devices, which are often VADs (Ventricular Assist Devices) that do not fully replace the heart.
• Over 2,100 SynCardia TAHs have been implanted in 27 countries globally, including major markets like the US, France, Germany, and the UK, indicating a significant global footprint for a highly specialized device.
• The company's ongoing operating losses and negative cash flows are common for medical device companies in the development and early commercialization stages, especially those investing heavily in R&D for next-generation products. However, the magnitude of the net loss increase and the gross loss are concerning compared to industry peers with established revenue streams.
• The substantial doubt about going concern, while mitigated by the IPO, suggests a higher financial risk profile compared to more mature, profitable medical device companies.

Corporate Governance

Legal Proceedings

• No material legal proceedings are currently pending against the company.

Related Party Transactions

• An unsecured promissory note (Versa Note) for $100,000 advanced to Versa Capital Management, LLC (shares common ownership with Sindex), with a balance of $112,000 (including accrued interest) as of June 30, 2025, remains uncollected.
• Various loans from Fang Family Fund, LLC and Fang Family Fund II, LLC (entities affiliated with an executive director) were consolidated into a $7.0 million convertible note on July 2, 2024, which was subsequently donated by Richard Fang to Nexus Science Foundation Inc. and Another Dimension Foundation.
• Senior Secured Notes: Borrowed $1.75 million from Fang Family Fund II, LLC in January and June 2025, bearing 6% interest, secured by all company assets.
• On July 1, 2025, amended a $250,000 related party working capital loan and issued a $93,633 loan to Hunniwell (a limited partner in Hunniwell Picard I, LLC, which owns a majority of common stock post-IPO) for travel expense reimbursements, and a $187,190 loan to Daniel Teo for severance, all under Senior Secured Notes terms.
• On July 8, 2025, borrowed $425,000 from Fang Family Fund I, LLC (affiliated with an executive director) under a loan agreement bearing 6% interest, due October 15, 2025, and secured by all company assets.
• On August 18, 2025, borrowed $450,000 from Fang Family Fund I, LLC under similar terms.

Stakeholder Impact

• **Shareholders:** Existing common shareholders experienced dilution from the IPO and conversion of preferred stock and convertible notes. The IPO provides liquidity but the increased net loss and going concern warning indicate continued risk. The stock split adjusted share counts.
• **Employees:** Research and development personnel decreased, potentially impacting future innovation capacity. Stock-based compensation continues to be a component of employee incentives.
• **Customers:** Continued product sales growth in the US, but cessation of rental revenues. The company's focus on next-generation TAHs aims to improve clinical outcomes and patient quality of life.
• **Creditors:** Several convertible notes are past due, indicating potential repayment challenges, though the IPO proceeds may alleviate some immediate pressure. Related party loans are secured by company assets.
• **Regulatory Bodies:** The company is subject to SEC filing requirements and is addressing material weaknesses in internal controls, which is critical for regulatory compliance.

Next Steps

• Utilize IPO proceeds to support market expansion via a joint venture in China.
• Fund research and development activities for next-generation products, including portable and hospital drivers, and a fully implantable system.
• Build sales, marketing, and distribution capabilities for the total artificial heart system, including increasing inventory and expanding the base of drivers.
• Repay existing debt and cover general operational expenses and working capital.
• Continue to implement remediation measures for material weaknesses in internal control over financial reporting, including hiring additional accounting personnel, establishing multi-level reviews, developing formal policies, and improving related party transaction monitoring.
• Work with lenders to extend maturity dates for past due convertible notes.
• Consolidate results of SynCardia Medical (Beijing), Inc. into consolidated financial statements if the company becomes publicly traded and contributes approximately $2.85 million for a 60% ownership interest.

Key Dates

Recommendation

The successful IPO and capital raise are critical for Picard Medical's immediate liquidity and address the going concern issue, which is a significant positive. However, the underlying operational performance shows a substantial increase in net loss, a shift from gross profit to gross loss, and high interest and derivative expenses. The company still faces material weaknesses in internal controls and has past-due related party debt. While the IPO provides a lifeline and the company has a unique FDA-approved product, the operational challenges and continued unprofitability suggest that significant risks remain. A 'hold' recommendation acknowledges the positive capital infusion and market position but advises caution due to ongoing financial and operational vulnerabilities, awaiting clearer signs of sustainable profitability and effective remediation of internal control issues.

Keywords

Medical Devices, Total Artificial Heart, SynCardia TAH, Cardiovascular, SEC Filing, 10-Q, IPO, Financial Results, Going Concern, Convertible Notes, Internal Controls, Biotechnology, Healthcare, FDA Approved